search
Back to results

Use of Tranexamic Acid in Liposculpture

Primary Purpose

Blood Loss, Surgical

Status
Completed
Phase
Phase 2
Locations
International
Study Type
Interventional
Intervention
Tranexamic acid
Sponsored by
Total Definer Research Group
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Blood Loss, Surgical focused on measuring Tranexamic Acid, Blood Loss, Liposculpture

Eligibility Criteria

20 Years - 45 Years (Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • Patients that underwent liposculpture as unique procedure, surgical time between 2 and 5 hours, age between 20 and 45 years old and BMI between 20 and 30 m2/kg.

Exclusion Criteria:

  • Patients that were operated of liposculpture and any additional procedure (Mammoplasty, tummy tuck, etc.), patients with history of thromboembolic disease or in Treatment with aspirin within 14 days before surgery or anticoagulants within 5 days prior to surgery, patients with history of epilepsy, patients with allergy to tranexamic acid, comorbidity grade III or IV according to ASA (American society of Anesthesiologists) and patients with prothrombin time (PT) and/or activated partial thromboplastin time (aPTT) >1.5 times the baseline.

Sites / Locations

  • Dhara clinic
  • Innovare hospital
  • Centro Medico de las Americas clinic

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Placebo Comparator

Experimental

Experimental

Arm Label

Placebo group

Intravenous group

Subcutaneous group

Arm Description

No use of tranexamic acid. Subcutaneous infiltration of normal saline solution plus 1 mg of epinephrine as required for the procedure.

A single dose of 1 gr of tranexamic acid (10 ml) IV, thirty minutes previous to the initiation of the surgery. Subcutaneous infiltration of normal saline solution plus 1 mg of epinephrine as required for the procedure.

A single dose of 1 gr of tranexamic acid (10 ml) in the total of the infiltration mixture, as follow: 4 liters of infiltration contents 2.5 ml of tranexamic acid plus 1 mg epinephrine 5 liters of infiltration contents 2 ml of tranexamic acid plus 1 mg epinephrine. 6 liters of infiltration contents 1.6 ml of tranexamic acid plus 1 mg epinephrine.

Outcomes

Primary Outcome Measures

Change in hemoglobin
All patients had hemoglobin tests taken prior to surgery, 24 hours postoperatively and 5 days postoperatively. We determine the hemoglobin loss points in each group by deduct the postoperative hemoglobin at day one to the preoperative hemoglobin (For hemoglobin loss at day 1) and the postoperative hemoglobin at day five to the preoperative hemoglobin (For hemoglobin loss at day 5).

Secondary Outcome Measures

Full Information

First Posted
June 9, 2020
Last Updated
June 11, 2020
Sponsor
Total Definer Research Group
search

1. Study Identification

Unique Protocol Identification Number
NCT04430777
Brief Title
Use of Tranexamic Acid in Liposculpture
Official Title
Use of Tranexamic Acid in Liposculpture: A Double-blind, Multicenter, Randomized Trial
Study Type
Interventional

2. Study Status

Record Verification Date
June 2020
Overall Recruitment Status
Completed
Study Start Date
January 17, 2019 (Actual)
Primary Completion Date
February 22, 2020 (Actual)
Study Completion Date
February 22, 2020 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Total Definer Research Group

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Blood loss during a surgical procedure is inevitable, its reduction is a key factor for surgical success. Also, to avoid progress to severe complications like hemodynamic decompensation, cardiac arrest or the need to blood transfusions. According to the Center for Disease Control (CDC), there is a usage of more than 17 million transfused blood products units per year. Blood transfusion is a convenient technique for reposition of blood during major bleed, but it involves several probable complications like anaphylaxis, bloodborne infections and others. Consequently, meticulous hemostasis during surgery is crucial to diminish blood loss. Hemostatic agents play a pivotal role during surgical time. Amongst them topical, energy-based and systemic agents are the vast majority. Tranexamic acid (TXA) is a lysine synthetic derivate that inhibits fibrinolysis by blocking the 5 lysine-binding sites to plasminogen. It has been used in clinical practice since 1962 and become very popular after 2010 when the CRASH-2 study showed a decreased risk of death in trauma patients. Tranexamic acid use is widely extended among diverse surgical fields: orthopedics, cardiac surgery and obstetrics. In plastic surgery it uses is limited mainly to craniofacial surgery as a local agent. The aim of this trial is to show the efficacy of tranexamic acid as hemostatic agent in liposuction and to compare its efficacy among different administration routes.
Detailed Description
In 3 plastic surgery centers, the investigators randomized patients in a double-blind, randomized, controlled trial comparing the clinical outcomes of different administration routes of TXA, intravenous versus subcutaneous versus placebo between January 2019 to February 2020. The study was approved by the Ethics committee at the central coordinating center and at each of the participating sites. The centers of the study were, Dhara clinic, Bogota, Colombia, Centro Medico de las Americas clinic, in Mérida, Mexico and Innovare hospital in Jalisco, Mexico. Once a month, the investigators performed only meetings between the researcher coordinator and delegates from each of the centers to audit the data collection and information registration. During the preoperative consultation, the study interventions were explained clearly to each participants. Participants were given adequate time to ponder the information, had any questions answered and gave their free and voluntary consent. A total of 141 participants were recollected. The primary outcome was the difference regarding to hemoglobin loss points between groups. All patients had hemoglobin and hematocrit tests taken prior to surgery, 24 hours postoperatively and 5 days postoperatively. The investigators determined the hemoglobin loss points in each group by deduct the postoperative hemoglobin at day one to the preoperative hemoglobin (For hemoglobin loss at day 1) and the postoperative hemoglobin at day five to the preoperative hemoglobin (For hemoglobin loss at day 5). As a secondary outcome, the investigators performed a subgroup analysis to determine the difference in hematological parameters (hemoglobin and hematocrit) between the groups. Sample size and Statistical Analysis Sample size was calculated using the online app from sealed envelope where 96 patients were required to have a 90% of chance of detecting, as significant at the 5% level, a difference between the mean postoperative Hb value from 10.5 g/dl in the control group to 11.5 g/dl in the experimental group and an estimated standard deviation (SD) of 1.5 g/dl. Since, the investigators planned two experimental approaches: Subcutaneous (SC) TA and Intravenous (IV) TA; 141 patients were randomized into 3 groups: 1. IV-TA group (n=47), 2. SC-TA group (n=47) and NS group. Demographic and clinical characteristics were described, hematological parameters were analyzed per group before surgery, at the immediate post-operative period, and at the fifth post-operative day. The descriptive analysis was made through means and medians according to the distribution of variables. For categorical variables, counts and percentages were used. The quantitative variables with parametric distribution were compared using ANOVA, and for variables with non-parametric distribution using Kruskal-Wallis test, while the frequencies of the qualitative variables were compared using Chi2 test. We used a boxplot to illustrate the differences between the means of the hemoglobin by group. Bilateral hypotheses were formulated at two tails with significance level less than 0.05. The data were collected in Microsoft excel and the statistical analysis were performed in the statistical program STATA version 15.0.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Blood Loss, Surgical
Keywords
Tranexamic Acid, Blood Loss, Liposculpture

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2, Phase 3
Interventional Study Model
Parallel Assignment
Model Description
Patients were randomly assigned to three groups: Placebo group, intravenous group and subcutaneous group according to the administration route of tranexamic acid
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
141 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Placebo group
Arm Type
Placebo Comparator
Arm Description
No use of tranexamic acid. Subcutaneous infiltration of normal saline solution plus 1 mg of epinephrine as required for the procedure.
Arm Title
Intravenous group
Arm Type
Experimental
Arm Description
A single dose of 1 gr of tranexamic acid (10 ml) IV, thirty minutes previous to the initiation of the surgery. Subcutaneous infiltration of normal saline solution plus 1 mg of epinephrine as required for the procedure.
Arm Title
Subcutaneous group
Arm Type
Experimental
Arm Description
A single dose of 1 gr of tranexamic acid (10 ml) in the total of the infiltration mixture, as follow: 4 liters of infiltration contents 2.5 ml of tranexamic acid plus 1 mg epinephrine 5 liters of infiltration contents 2 ml of tranexamic acid plus 1 mg epinephrine. 6 liters of infiltration contents 1.6 ml of tranexamic acid plus 1 mg epinephrine.
Intervention Type
Drug
Intervention Name(s)
Tranexamic acid
Intervention Description
Administration of tranexamic acid 1 gr either intravenously or subcutaneously
Primary Outcome Measure Information:
Title
Change in hemoglobin
Description
All patients had hemoglobin tests taken prior to surgery, 24 hours postoperatively and 5 days postoperatively. We determine the hemoglobin loss points in each group by deduct the postoperative hemoglobin at day one to the preoperative hemoglobin (For hemoglobin loss at day 1) and the postoperative hemoglobin at day five to the preoperative hemoglobin (For hemoglobin loss at day 5).
Time Frame
Change from Baseline Hemoglobin at first posoperative and fifth posoperative day

10. Eligibility

Sex
All
Minimum Age & Unit of Time
20 Years
Maximum Age & Unit of Time
45 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Patients that underwent liposculpture as unique procedure, surgical time between 2 and 5 hours, age between 20 and 45 years old and BMI between 20 and 30 m2/kg. Exclusion Criteria: Patients that were operated of liposculpture and any additional procedure (Mammoplasty, tummy tuck, etc.), patients with history of thromboembolic disease or in Treatment with aspirin within 14 days before surgery or anticoagulants within 5 days prior to surgery, patients with history of epilepsy, patients with allergy to tranexamic acid, comorbidity grade III or IV according to ASA (American society of Anesthesiologists) and patients with prothrombin time (PT) and/or activated partial thromboplastin time (aPTT) >1.5 times the baseline.
Facility Information:
Facility Name
Dhara clinic
City
Bogota
Country
Colombia
Facility Name
Innovare hospital
City
Jalisco
Country
Mexico
Facility Name
Centro Medico de las Americas clinic
City
Merida
Country
Mexico

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
23839785
Citation
Ker K, Prieto-Merino D, Roberts I. Systematic review, meta-analysis and meta-regression of the effect of tranexamic acid on surgical blood loss. Br J Surg. 2013 Sep;100(10):1271-9. doi: 10.1002/bjs.9193. Epub 2013 Jul 9.
Results Reference
background
PubMed Identifier
28938364
Citation
Rohrich RJ, Cho MJ. The Role of Tranexamic Acid in Plastic Surgery: Review and Technical Considerations. Plast Reconstr Surg. 2018 Feb;141(2):507-515. doi: 10.1097/PRS.0000000000003926.
Results Reference
background
PubMed Identifier
31455576
Citation
Taam J, Yang QJ, Pang KS, Karanicolas P, Choi S, Wasowicz M, Jerath A. Current Evidence and Future Directions of Tranexamic Acid Use, Efficacy, and Dosing for Major Surgical Procedures. J Cardiothorac Vasc Anesth. 2020 Mar;34(3):782-790. doi: 10.1053/j.jvca.2019.06.042. Epub 2019 Jul 4.
Results Reference
background

Learn more about this trial

Use of Tranexamic Acid in Liposculpture

We'll reach out to this number within 24 hrs